ReviewAdvances in nutrition (Bethesda, Md.)2026
Impact of Milk Fat Globule Membrane and Its Associated Polar Lipids on Markers of Cardiometabolic Disease and Cognitive Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials in Adults.
Review in Advances in nutrition (Bethesda, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Milk fat globule membrane (MFGM) and its associated milk polar lipids (MPLs) are bioactive components of dairy fat with emerging relevance for cardiometabolic and cognitive health. This systematic review and meta-analysis evaluated the effects of bovine-derived MFGM/MPL on fasting and postprandial cardiometabolic disease risk markers and cognitive function in disease-free adults, compared with isoenergetic dairy products or supplements low in these components. Searches of PubMed (Medical Literature Analysis and Retrieval System Online), Embase, and Cochrane Central identified randomized controlled trials (RCTs) comparing MFGM/MPL-containing foods or supplements with isoenergetic dairy comparators low in these components. Risk of bias (RoB) was assessed using the Cochrane RoB 2.0 tool. Random-effects meta-analyses were performed for outcomes reported in ≥3 studies, and the certainty of evidence for critical outcomes was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations approach. Of 730 records screened, 13 studies (14 articles) met inclusion criteria (RoB: low to some concerns). Pooled analyses demonstrated that 2 to 16 wk of MFGM/MPL intake (19.8-5000 mg/d) reduced fasting total cholesterol [weighted mean difference (WMD): -0.18 mmol/L; 95% confidence interval (CI): -0.30, -0.07], low-density lipoprotein cholesterol (WMD: -0.12 mmol/L; 95% CI: -0.22, -0.03), apolipoprotein B concentrations (WMD: -0.05 g/L; 95% CI: -0.09, -0.01), and the total cholesterol:high-density lipoprotein (HDL) cholesterol ratio (WMD: -0.17; 95% CI: -0.33, -0.01), with low heterogeneity (I
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.